Tyra Biosciences, Inc. is a clinical-stage biotechnology company dedicated to developing precision medicines that target Fibroblast Growth Factor Receptor (FGFR) biology. Headquartered in Carlsbad, California, the company aims to overcome acquired tumor resistance and improve outcomes for patients with cancer and genetically defined conditions.
At the core of Tyra's business model is its proprietary in-house discovery platform, SNÅP. This platform enables rapid and precise structural drug design through iterative molecular snapshots, helping to predict genetic alterations that cause resistance to existing therapies. By leveraging structure-based drug design, computational chemistry, and genetic analysis, Tyra develops highly selective small molecule inhibitors designed to work against both wild-type and mutant drug targets.
As a clinical-stage entity, Tyra Biosciences is currently pre-revenue and does not generate product sales, funding its research and development primarily through equity financing. The company's pipeline is led by TYRA-300 (oral dabogratinib), a potential first-in-class selective FGFR3 inhibitor currently in Phase 1/2 clinical trials for metastatic urothelial carcinoma (mUC) and non-muscle invasive bladder cancer (NMIBC). TYRA-300 is also in development for skeletal dysplasias, including achondroplasia. Other pipeline candidates include TYRA-200, which is being evaluated in clinical trials for intrahepatic cholangiocarcinoma, and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra competes in the highly specialized precision oncology space against other biopharmaceutical companies developing targeted kinase inhibitors and therapies for FGFR-altered tumors.
